US Bancorp DE Has $10.09 Million Position in Becton, Dickinson and Company $BDX

US Bancorp DE reduced its holdings in Becton, Dickinson and Company (NYSE:BDX) by 15.6% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 58,564 shares of the medical instruments supplier’s stock after selling 10,811 shares during the quarter. US Bancorp DE’s holdings in Becton, Dickinson and Company were worth $10,088,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in BDX. GQG Partners LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $689,833,000. Vanguard Group Inc. grew its position in shares of Becton, Dickinson and Company by 4.7% in the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock valued at $6,414,322,000 after purchasing an additional 1,259,750 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $211,097,000. Kingstone Capital Partners Texas LLC acquired a new stake in shares of Becton, Dickinson and Company in the second quarter valued at about $155,080,000. Finally, Massachusetts Financial Services Co. MA grew its position in shares of Becton, Dickinson and Company by 10.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock valued at $1,567,654,000 after purchasing an additional 667,957 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company’s stock, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,023 shares of company stock valued at $562,036 in the last quarter. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Stock Down 1.4%

NYSE BDX opened at $186.41 on Friday. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The stock’s 50 day moving average is $190.07 and its two-hundred day moving average is $186.03. The company has a market capitalization of $53.43 billion, a price-to-earnings ratio of 33.53, a PEG ratio of 1.46 and a beta of 0.25. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The company had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. Equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s payout ratio is presently 74.82%.

Wall Street Analyst Weigh In

BDX has been the topic of several research analyst reports. Argus increased their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Wells Fargo & Company increased their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Royal Bank Of Canada initiated coverage on shares of Becton, Dickinson and Company in a research note on Thursday, September 25th. They issued a “sector perform” rating and a $211.00 target price for the company. Finally, Morgan Stanley increased their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $205.40.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.